Skip to main content
Clinical Trials/NL-OMON41706
NL-OMON41706
Completed
Not Applicable

Efficacy of CryoBalloon Focal Ablation System on Human Esophageal Barrett*s Epithelium - Efficacy EBCA focal

C2Therapeutics0 sites40 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
esophageal cancer
Sponsor
C2Therapeutics
Enrollment
40
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
C2Therapeutics

Eligibility Criteria

Inclusion Criteria

  • a) Patients with known Barrett\*s esophagus, scheduled for treatment with focal radiofrequency ablation (HALO\-90\) \[i.e. in patients with islands or residual Barrett\*s after circumferential radiofrequency ablation (HALO\-360\) or in patients for whom circumferential radiofrequency ablation is not feasible], during which the cryoablation may be performed.
  • b) Patient is 18 to 80 years of age at the time of consent (inclusive).
  • c) Patient has provided written Informed Consent (IC) using an Informed Consent Form (ICF) that has been approved by the Institution\*s reviewing IRB/EC.
  • d) Patient is willing and able to comply with all Clinical Investigation Plan (CIP) requirements.
  • e) Patient is deemed operable per standard institutional criteria.
  • f) Each patient will have one (group of) island of BE \*1 cm2 where the Cryoballoon Focal Ablation System can be successfully positioned within the BE lesion.
  • g) BE lesion within the treatment zone should be flat.

Exclusion Criteria

  • a) Esophageal stenosis preventing advancement of a therapeutic endoscope and/or within 4 cm of treatment zone.
  • b) Patient has a known history of unresolved drug or alcohol dependency that would limit ability to comprehend or follow instructions related to informed consent, post treatment instructions or follow\-up guidelines.
  • c) Patient refuses or is unable to provide written informed consent.
  • d) Patients that are pregnant.
  • e) Patient with endoscopically active inflammation in the treatment zone.
  • f) Endoscopically visible abnormalities such as masses or nodules requiring endoscopic resection.

Outcomes

Primary Outcomes

Not specified

Similar Trials